nach oben

Erschienen in:

01.10.2012 | Educational Series – BLUE SERIES

The EMT signaling pathways in endometrial carcinoma

verfasst von: Eva Colas, Nuria Pedrola, Laura Devis, Tugçe Ertekin, Irene Campoy, Elena Martínez, Marta Llauradó, Marina Rigau, Mireia Olivan, Marta Garcia, Silvia Cabrera, Antonio Gil-Moreno, Jordi Xercavins, Josep Castellvi, Angel Garcia, Santiago Ramon y Cajal, Gema Moreno-Bueno, Xavier Dolcet, Francesc Alameda, Jose Palacios, Jaime Prat, Andreas Doll, Xavier Matias-Guiu, Miguel Abal, Jaume Reventos

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Abstract

Endometrial cancer (EC) is the most common gynecologic malignancy of the female genital tract and the fourth most common neoplasia in women. In EC, myometrial invasion is considered one of the most important prognostic factors. For this process to occur, epithelial tumor cells need to undergo an epithelial to mesenchymal transition (EMT), either transiently or stably, and to differing degrees. This process has been extensively described in other types of cancer but has been poorly studied in EC. In this review, several features of EMT and the main molecular pathways responsible for triggering this process are investigated in relation to EC. The most common hallmarks of EMT have been found in EC, either at the level of E-cadherin loss or at the induction of its repressors, as well as other molecular alterations consistent with the mesenchymal phenotype-like L1CAM and BMI-1 up-regulation. Pathways including progesterone receptor, TGFβ, ETV5 and microRNAs are deeply related to the EMT process in EC.

Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10–17PubMedCrossRef

Zannoni GF, Scambia G, Gallo D (2011) The dualistic model of endometrial cancer: the challenge of classifying grade 3 endometrioid carcinoma. Gynecol Oncol. doi:10.1016/j.ygyno.2011.09.036

Llauradó M et al (2011) Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. Mol Cell Endocrinol. doi:10.1016/j.mce.2011.10.003

Amant F et al (2005) Endometrial cancer. Lancet 366:491–505PubMedCrossRef

Yeramian A et al (2012) Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene. doi:10.1038/onc.2012.76

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29PubMedCrossRef

Abal M et al (2007) Molecular determinants of invasion in endometrial cancer. Clin Transl Oncol 9:272–277PubMedCrossRef

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674PubMedCrossRef

Moreno-Bueno G, Portillo F, Cano A (2008) Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 27:6958–6969PubMedCrossRef

10.

Yang J, Weinberg RA (2008) Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14:818–829PubMedCrossRef

11.

Thiery JP, Morgan M (2004) Breast cancer progression with a Twist. Nat Med 10:777–778PubMedCrossRef

12.

Kang Y, Massague J (2004) Epithelial–mesenchymal transitions: twist in development and metastasis. Cell 118:277–279PubMedCrossRef

13.

Mueller MM, Fusenig NE (2004) Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4:839–849PubMedCrossRef

14.

Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332–337PubMedCrossRef

15.

Barrallo-Gimeno A, Nieto MA (2005) The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 132:3151–3161PubMedCrossRef

16.

De Craene B, van Roy F, Berx G (2005) Unraveling signaling cascades for the Snail family of transcription factors. Cell Signal 17:535–547PubMedCrossRef

17.

Huber M, Kraut N, Beug H (2005) Molecular requirements for epithelial–mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548–558PubMedCrossRef

18.

Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol 7:131–142PubMedCrossRef

19.

Micalizzi D, Farabaugh S, Ford H (2010) Epithelial–mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 15:117–134PubMedCrossRef

20.

Hurt EM, Saykally JN, Anose BM, Kalli KR, Sanders MM (2008) Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights. Mol Cell Biochem 318:89–99PubMedCrossRef

21.

Singh M et al (2008) ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol 21:912–923PubMedCrossRef

22.

Kyo S et al (2006) High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol 37:431–438PubMedCrossRef

23.

Blechschmidt K et al (2007) The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn Mol Pathol 16:222–228PubMedCrossRef

24.

Shih H-C et al (2004) Immunohistochemical expression of E-cadherin and beta-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear beta-catenin expression. Anticancer Res 24:3843–3850PubMed

25.

Scholten AN, Aliredjo R, Creutzberg CL, Smit VTHB (2006) Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int J Gynecol Cancer 16:1379–1385PubMedCrossRef

26.

Sakuragi N et al (1994) Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol 53:183–189PubMedCrossRef

27.

Moreno-Bueno G et al (2003) Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 199:471–478PubMedCrossRef

28.

Stefansson IM, Salvesen HB, Akslen LA (2004) Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 22:1242–1252PubMedCrossRef

29.

Mell LK et al (2004) Prognostic significance of E-cadherin protein expression in pathological stage I–III endometrial cancer. Clin Cancer Res 10:5546–5553PubMedCrossRef

30.

Leblanc M et al (2001) Alteration of CD44 and cadherins expression: possible association with augmented aggressiveness and invasiveness of endometrial carcinoma. Virchows Arch 438:78–85PubMedCrossRef

31.

Huszar M et al (2010) Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol 220:551–561PubMedCrossRef

32.

Pfeifer M et al (2010) L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. BMC Mol Biol 11:64PubMedCrossRef

33.

Lee H et al(2012) Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer. Hum Pathol. doi:10.1016/j.humpath.2011.12.019

34.

Vonlanthen S et al (2001) The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84:1372–1376PubMedCrossRef

35.

Guo B-H et al (2011) Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol. Cancer 10:10PubMedCrossRef

36.

Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115:1503–1521PubMedCrossRef

37.

Zhang F, Sui L, Xin T (2008) Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. Exp Oncol 30:70–74PubMed

38.

Honig A et al (2010) Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer. Anticancer Res 30:1559–1564PubMed

39.

Dong P et al (2011) MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 10:99PubMedCrossRef

40.

Stewart CJR, Little L (2009) Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial–mesenchymal transition. Histopathology 55:91–101PubMedCrossRef

41.

Hanekamp EE et al (2005) Differences in invasive capacity of endometrial cancer cell lines expressing different progesterone receptor isotypes: possible involvement of cadherins. J Soc Gynecol Invest 12:278–284CrossRef

42.

Dai D, Wolf DM, Litman ES, White MJ, Leslie KK (2002) Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 62:881–886PubMed

43.

Hanekamp EE et al (2002) Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer. Eur J Cancer 38(Suppl 6):S71–S72PubMedCrossRef

44.

Van der Horst PH et al (2012) Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer. PLoS One 7(1):e30840

45.

Fujita N et al (2003) MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 113:207–219PubMedCrossRef

46.

Dandachi N et al (2001) Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. J Pathol 193:181–189PubMedCrossRef

47.

Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM (1988) Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158:796–807PubMed

48.

Jeon Y-T et al (2006) Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. Cancer Lett 239:198–204PubMedCrossRef

49.

Thigpen JT et al (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17:1736–1744PubMed

50.

Hanekamp EE et al (2003) Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 9:4190–4199PubMed

51.

Wang Y et al (2009) Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res 15:5784–5793PubMedCrossRef

52.

Massagué J (2008) TGFbeta in Cancer. Cell 134:215–230PubMedCrossRef

53.

Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 425:577–584PubMedCrossRef

54.

Parekh TV et al (2002) Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition. Cancer Res 62:2778–2790PubMed

55.

Muinelo-Romay L et al (2011) High-risk endometrial carcinoma profiling identifies TGF-β1 as a key factor in the initiation of tumor invasion. Mol Cancer Ther 10:1357–1366PubMedCrossRef

56.

Lei X, Wang L, Yang J, Sun L-Z (2009) TGFbeta signaling supports survival and metastasis of endometrial cancer cells. Cancer Manag Res 2009:15–24PubMed

57.

de Launoit Y et al (2006) The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta 1766:79–87PubMed

58.

Graves BJ, Petersen JM (1998) Specificity within the ets family of transcription factors. Adv Cancer Res 75:1–55PubMedCrossRef

59.

Planaguma J et al (2005) Up-regulation of ERM/ETV5 correlates with the degree of myometrial infiltration in endometrioid endometrial carcinoma. J Pathol 207:422–429PubMedCrossRef

60.

Llauradó M et al (2012) ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. Int J Cancer 130:1532–1543PubMedCrossRef

61.

Colas E et al (2012) ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas. Oncogene. doi:10.1038/onc.2011.632

62.

Monge M et al (2007) ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res 67:6753–6759PubMedCrossRef

63.

Monge M et al (2009) Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis 30:1288–1297PubMedCrossRef

64.

Monge M et al (2009) Subtractive proteomic approach to the endometrial carcinoma invasion front. J Proteome Res 8:4676–4684PubMedCrossRef

65.

Ebert MS, Sharp PA (2012) Roles for MicroRNAs in conferring robustness to biological processes. Cell 149:515–524PubMedCrossRef

66.

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297PubMedCrossRef

67.

Lujambio A, Lowe SW (2012) The microcosmos of cancer. Nature 482:347–355PubMedCrossRef

68.

Castilla MA et al (2011) Micro-RNA signature of the epithelial–mesenchymal transition in endometrial carcinosarcoma. J Pathol 223:72–80PubMedCrossRef

69.

Kong W et al (2008) MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 28:6773–6784PubMedCrossRef

70.

Howe EN, Cochrane DR, Richer JK (2011) Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res 13:R45PubMedCrossRef

71.

Cano A, Nieto MA (2008) Non-coding RNAs take centre stage in epithelial-to-mesenchymal transition. Trends Cell Biol 18:357–359PubMedCrossRef

Titel: The EMT signaling pathways in endometrial carcinoma
verfasst von: Eva Colas
Nuria Pedrola
Laura Devis
Tugçe Ertekin
Irene Campoy
Elena Martínez
Marta Llauradó
Marina Rigau
Mireia Olivan
Marta Garcia
Silvia Cabrera
Antonio Gil-Moreno
Jordi Xercavins
Josep Castellvi
Angel Garcia
Santiago Ramon y Cajal
Gema Moreno-Bueno
Xavier Dolcet
Francesc Alameda
Jose Palacios
Jaime Prat
Andreas Doll
Xavier Matias-Guiu
Miguel Abal
Jaume Reventos
Publikationsdatum: 01.10.2012
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 10/2012
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0866-3

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The EMT signaling pathways in endometrial carcinoma

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2012

Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells

Defects in mTR stability and telomerase activity produced by the Dkc1 A353V mutation in dyskeratosis congenita are rescued by a peptide from the dyskerin TruB domain

Intensity modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) in a patient with left breast cancer and pectus excavatum

Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA

Epidemiology and prevalence of oropharyngeal candidiasis in Spanish patients with head and neck tumors undergoing radiotherapy treatment alone or in combination with chemotherapy

The SGBS cell strain as a model for the in vitro study of obesity and cancer

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie